NASDAQ: NMRA - Neumora Therapeutics, Inc. Common Stock

Altı ay boyunca karlılık: +5.9%
Sektör: Healthcare

Promosyon programı Neumora Therapeutics, Inc. Common Stock

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Daha fazla ayrıntı
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. The company was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

Цена ао 11.85
ISIN US6409791000
EBITDA -0.0954
EV/EBITDA 1.99
Сайт https://neumoratx.com
Число акций ао 0.15883 млрд
P/BV 5.77
Валюта usd
IPO date 2023-09-14
Sector Health Care
Industry Pharmaceuticals
Валюта отчета usd
Günlük fiyat değişimi: -28.14% (16.49)
Haftalık fiyat değişimi: -17.36% (14.34)
Aylık fiyat değişimi: +0.1691% (11.83)
3 ayda fiyat değişimi: +2.07% (11.61)
Altı ayda fiyat değişimi: +5.9% (11.19)
Yıllık fiyat değişimi: +19.58% (9.91)
Yılbaşından bu yana fiyat değişimi: +2.33% (11.58)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 5.77 2
P/E 0 0
EV/EBITDA -12.47 0
Toplam: 2.25

Yeterlik

İsim Anlam Seviye
ROA, % -47.55 0
ROE, % -50.3 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0279 10
Toplam: 9.4

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 0 0
karlılık Ebitda, % 96.57 9
karlılık EPS, % 127.36 10
Toplam: 7.8
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Softbank Group Corporation 7646916 4.81
FMR, LLC 6373129 4.01
MIC Capital Management UK LLP 4460700 2.81
ICONIQ Capital, LLC 3398628 2.14
Wellcome Trust Ltd (the) As Trustee Of The Wellcome Trust 3309123 2.08
Artal Group S.A. 2552702 1.61
EcoR1 Capital, LLC 2071450 1.3
Avidity Partners Management, LP 1990632 1.25
Johnson & Johnson 1849445 1.16
Citadel Advisors Llc 1843291 1.16

ETF Paylaşmak, % Yıllık karlılık, % Temettüler, %
iShares U.S. Pharmaceuticals ETF 0.41562 17.60673599431 1.97922
iShares Morningstar Small-Cap ETF 0.01976 30.095066471445 1.60498
iShares Russell 2000 Growth ETF 0.08025 38.042556988 0.6026
iShares Russell 3000 ETF 0.00212 32.57283798366 1.43482
iShares Morningstar Small-Cap ETF 0.01976 391.25300933451 1.60498



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Paul L. Berns Co-Founder & Executive Chairman 1.65M 1967 (57 yıllar)
Mr. Henry O. Gosebruch President, CEO & Director 3.33M 1973 (51 yıl)
Ms. Carol Suh Co-Founder & COO N/A 1990 (34 yıl)
Dr. Rajesh Manchanda Ph.D. Chief Technical Operations Officer N/A 1966 (58 yıllar)
Mr. Nicholas Brandon Ph.D. Chief Scientific Officer N/A 1974 (50 yıllar)
Mr. Jason G. Duncan Chief Legal Officer 315k 1974 (50 yıllar)
Mr. Michael Lee Milligan Principal Accounting Officer N/A
Mr. Robert Lenz M.D., Ph.D. Head of Research & Development 770.29k 1971 (53 yıl)
Dr. Joshua Pinto Ph.D. Chief Financial Officer 876.64k 1985 (39 yıllar)
Dr. Robert Michael Poole FACP, M.D. Co-Founder & Advisor 1957 (67 yıllar)

Adres: United States, Watertown. MA, 490 Arsenal Way - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://neumoratx.com